AR103078A1 - Derivados de fumagilol - Google Patents
Derivados de fumagilolInfo
- Publication number
- AR103078A1 AR103078A1 ARP150104152A ARP150104152A AR103078A1 AR 103078 A1 AR103078 A1 AR 103078A1 AR P150104152 A ARP150104152 A AR P150104152A AR P150104152 A ARP150104152 A AR P150104152A AR 103078 A1 AR103078 A1 AR 103078A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- substituted
- heteroaryl
- halo
- alkyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), un estereoisómero de este o una sal farmacéuticamente aceptable del compuesto o estereoisómero, donde: R¹ y R² se seleccionan cada uno independientemente de fenilo, heteroarilo C₃₋₅, -OR⁴, y -N(R⁴)R⁵, donde cada fenilo y heteroarilo C₃₋₅ está independientemente sustituido con entre 0 y 3 Rᵃ, y cada heteroarilo C₃₋₅ tiene átomos de 5 ó 6 anillos de los cuales 1 ó 2 son heteroátomos que se seleccionan independientemente de N, O, y S; cada Rᵃ se selecciona independientemente de halo, -CN, R³, y R⁴; cada R³ se selecciona independientemente de -OR⁴, -N(R⁴)R⁵, -NR⁴C(O)R⁶, -NR⁴C(O)OR⁵, -C(O)OR⁴, -C(O)N(R⁴)R⁵, -C(O)N(R⁴)OR⁵, -C(O)N(R⁴)S(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -SR⁴, -S(O)R⁶, -S(O)₂R⁶, y -S(O)₂N(R⁴)R⁵; cada R⁴ y R⁵ se selecciona independientemente de (a) alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ cada uno sustituido con entre 0 y 3 Rᵇ, y (b) cicloalquilo C₃₋₈-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno sustituido con entre 0 y 3 Rᶜ; cada R⁶ se selecciona independientemente de (a) alquilo C₁₋₆, que está sustituido con entre 0 y 3 Rᵇ, y (b) cicloalquilo C₃₋₈-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno sustituido con entre 0 y 3 Rᵈ; cada Rᵇ se selecciona independientemente de halo, -CN, y R⁷; cada Rᶜ se selecciona independientemente de (a) halo, -CN, y R⁷, y (b) alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆, cada uno sustituido con entre 0 y 3 Rᵇ; cada Rᵈ se selecciona independientemente de (a) halo, -CN, y R⁷, y (b) alquilo C₁₋₆, que está sustituido con entre 0 y 3 Rᵇ; cada R⁷ se selecciona independientemente de -OR⁸, -N(R⁸)R⁹, -NR⁸C(O)R⁹, -NR⁸C(O)OR⁹, -C(O)OR⁸, -C(O)N(R⁸)R⁹, -C(O)N(R⁸)OR⁹, -C(O)N(R⁸)S(O)₂R⁹, -N(R⁸)S(O)₂R⁹, -SR⁸, -S(O)R⁸, -S(O)₂R⁸, y -S(O)₂N(R⁸)R⁹; cada R⁸ y R⁹ se selecciona independientemente de alquilo C₁₋₆, cicloalquilo C₃₋₈-(CH₂)ₘ-, y heterociclilo C₂₋₆-(CH₂)ₘ-, cada uno sustituido con entre 0 y 3 sustituyentes que se seleccionan independientemente de halo y -CN; y cada m se selecciona independientemente de 0, 1, 2, 3, y 4; donde cada resto heteroarilo que se enumera en R⁴, R⁵, y R⁶ tiene independientemente de 1 a 4 heteroátomos que se seleccionan independientemente de N, O y S, y cada resto heterociclilo que se enumera en R⁴, R⁵, R⁶, y R⁸ tiene independientemente de 1 a 4 heteroátomos que se seleccionan independientemente de N, O, y S.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094823P | 2014-12-19 | 2014-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103078A1 true AR103078A1 (es) | 2017-04-12 |
Family
ID=55071249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104152A AR103078A1 (es) | 2014-12-19 | 2015-12-17 | Derivados de fumagilol |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9827255B2 (es) |
| EP (1) | EP3233870B1 (es) |
| JP (1) | JP2018500329A (es) |
| KR (1) | KR20170099973A (es) |
| CN (1) | CN107207547A (es) |
| AR (1) | AR103078A1 (es) |
| AU (1) | AU2015364477A1 (es) |
| BR (1) | BR112017012965A2 (es) |
| CA (1) | CA2971282A1 (es) |
| CL (1) | CL2017001602A1 (es) |
| CO (1) | CO2017007189A2 (es) |
| CR (1) | CR20170332A (es) |
| DO (1) | DOP2017000138A (es) |
| EA (1) | EA032431B1 (es) |
| EC (1) | ECSP17045054A (es) |
| ES (1) | ES2702026T3 (es) |
| IL (1) | IL252908A0 (es) |
| MX (1) | MX2017007926A (es) |
| PE (1) | PE20171141A1 (es) |
| PH (1) | PH12017501134A1 (es) |
| SG (1) | SG11201704985VA (es) |
| TN (1) | TN2017000254A1 (es) |
| TW (1) | TW201636342A (es) |
| UY (1) | UY36450A (es) |
| WO (1) | WO2016100778A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
| KR20210005100A (ko) * | 2018-04-20 | 2021-01-13 | 더 유니버시티 오브 버몬트 앤드 스테이트 애그리컬쳐 칼리지 | 선택된 환자에서 심혈관 질환을 치료하기 위한 조성물 및 방법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| ATE150750T1 (de) | 1988-09-01 | 1997-04-15 | Takeda Chemical Industries Ltd | Fumagillol-derivate |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JPH1081631A (ja) * | 1996-07-17 | 1998-03-31 | Takeda Chem Ind Ltd | 癌転移または再発抑制剤 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| US6306819B1 (en) | 1997-10-31 | 2001-10-23 | Massachusetts Institute Of Technology | Method for regulating size of vascularized normal tissue |
| KR100357542B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| US7084108B2 (en) | 2000-11-01 | 2006-08-01 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| DE60233420D1 (de) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| AU2003230852B2 (en) | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| CA2594951A1 (en) * | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| MX2010005857A (es) | 2007-11-28 | 2010-11-22 | Mersana Therapeutics Inc | Conjugados de analogos de fumagillina biodegradables biocompatibles. |
| US8299067B2 (en) | 2008-03-27 | 2012-10-30 | Versitech Limited | 5-demethoxyfumagillol and derivatives thereof |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| AU2011239414A1 (en) * | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
| MX342257B (es) * | 2011-03-08 | 2016-09-21 | Zafgen Inc | Derivados y análogos de oxaspiro [2.5] octano. |
| FR2973376B1 (fr) | 2011-03-28 | 2013-05-10 | Atlanthera | Derives utiles dans le traitement ou la prevention de tumeurs osseuses |
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
-
2015
- 2015-12-14 TW TW104141948A patent/TW201636342A/zh unknown
- 2015-12-17 UY UY0001036450A patent/UY36450A/es not_active Application Discontinuation
- 2015-12-17 AR ARP150104152A patent/AR103078A1/es unknown
- 2015-12-18 MX MX2017007926A patent/MX2017007926A/es unknown
- 2015-12-18 AU AU2015364477A patent/AU2015364477A1/en not_active Abandoned
- 2015-12-18 CR CR20170332A patent/CR20170332A/es unknown
- 2015-12-18 EA EA201791398A patent/EA032431B1/ru not_active IP Right Cessation
- 2015-12-18 SG SG11201704985VA patent/SG11201704985VA/en unknown
- 2015-12-18 TN TN2017000254A patent/TN2017000254A1/en unknown
- 2015-12-18 CN CN201580074539.4A patent/CN107207547A/zh active Pending
- 2015-12-18 US US14/974,033 patent/US9827255B2/en not_active Expired - Fee Related
- 2015-12-18 ES ES15820800T patent/ES2702026T3/es active Active
- 2015-12-18 EP EP15820800.9A patent/EP3233870B1/en active Active
- 2015-12-18 CA CA2971282A patent/CA2971282A1/en not_active Abandoned
- 2015-12-18 WO PCT/US2015/066594 patent/WO2016100778A1/en active Application Filing
- 2015-12-18 PE PE2017001074A patent/PE20171141A1/es not_active Application Discontinuation
- 2015-12-18 KR KR1020177020240A patent/KR20170099973A/ko unknown
- 2015-12-18 JP JP2017532117A patent/JP2018500329A/ja active Pending
- 2015-12-18 BR BR112017012965A patent/BR112017012965A2/pt not_active Application Discontinuation
-
2017
- 2017-06-13 DO DO2017000138A patent/DOP2017000138A/es unknown
- 2017-06-14 IL IL252908A patent/IL252908A0/en unknown
- 2017-06-16 PH PH12017501134A patent/PH12017501134A1/en unknown
- 2017-06-19 CL CL2017001602A patent/CL2017001602A1/es unknown
- 2017-07-12 EC ECIEPI201745054A patent/ECSP17045054A/es unknown
- 2017-07-18 CO CONC2017/0007189A patent/CO2017007189A2/es unknown
- 2017-10-27 US US15/796,519 patent/US10328089B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CO2017007189A2 (es) | 2017-10-20 |
| DOP2017000138A (es) | 2017-07-31 |
| KR20170099973A (ko) | 2017-09-01 |
| EA201791398A1 (ru) | 2017-10-31 |
| US9827255B2 (en) | 2017-11-28 |
| EP3233870A1 (en) | 2017-10-25 |
| ES2702026T3 (es) | 2019-02-27 |
| CN107207547A (zh) | 2017-09-26 |
| US10328089B2 (en) | 2019-06-25 |
| JP2018500329A (ja) | 2018-01-11 |
| EP3233870B1 (en) | 2018-10-31 |
| CR20170332A (es) | 2017-10-05 |
| PE20171141A1 (es) | 2017-08-09 |
| WO2016100778A1 (en) | 2016-06-23 |
| MX2017007926A (es) | 2017-09-27 |
| TW201636342A (zh) | 2016-10-16 |
| IL252908A0 (en) | 2017-08-31 |
| PH12017501134A1 (en) | 2017-11-27 |
| UY36450A (es) | 2016-07-29 |
| AU2015364477A1 (en) | 2017-07-13 |
| US20180050051A1 (en) | 2018-02-22 |
| ECSP17045054A (es) | 2017-10-31 |
| TN2017000254A1 (en) | 2018-10-19 |
| SG11201704985VA (en) | 2017-07-28 |
| CA2971282A1 (en) | 2016-06-23 |
| BR112017012965A2 (pt) | 2018-01-09 |
| US20160175332A1 (en) | 2016-06-23 |
| EA032431B1 (ru) | 2019-05-31 |
| CL2017001602A1 (es) | 2018-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110405A1 (es) | Compuestos | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| NZ732810A (en) | Picolinamides and other compounds | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |